ABSTRACT STUDY ON THE USE OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EF AT THE INTENSIVE CARE DEPARTMENT OF AN GIANG CARDIOVASCULAR HOSPITAL
Main Article Content
Abstract
Background:Heart failure with reduced ejection fraction is a very common disease, especially in elderly patients treated in the intensive care unit. Objective: To evaluate the clinical and paraclinical characteristics and the effectiveness of treating patients with heart failure with reduced ejection fraction with dapagliflozin in the intensive care unit, An Giang Cardiovascular Hospital in 2024. Materials and methods: A retrospective cross-sectional study was conducted on 130 patients with heart failure with reduced ejection fraction treated with standard background regimens, divided into two groups: group A of 65 patients treated with dapagliflozin and group B of 65 patients not using dapagliflozin. Results: The mean ages of the dapagliflozin-treated and untreated groups were 69.5 ± 10.2 and 71.3 ± 11.5 years, respectively; the mean ejection fractions were 28.1 ± 3.5% and 30.4 ± 3.9%, respectively. The rates of adverse events such as urinary tract infection, hypotension, hyperkalemia, bradycardia, hypoglycemia, and acute kidney injury were not significantly different in the dapagliflozin-treated group compared with the untreated group (p > 0.05). The rate of hospitalization for heart failure in the dapagliflozin-treated group (15.3%) was lower than that of the other group (41.5%) (p = 0.040). Conclusion: Dapagliflozin demonstrated certain therapeutic benefits in the management of HFrEF, with a comparable incidence of adverse events to that observed in patients not receiving the drug.
Keywords
Heart failure with reduced ejection fraction, dapagliflozin, intensive care unit
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Phạm Nguyễn Vinh. Khuyến cáo của hội tim mạch quốc gia về chẩn đoán và điều trị suy tim cấp và mạn. Hội tim mạch học quốc gia Việt Nam. 2022. 15-23.
3. Jones NR, Roalfe AK. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019. 21(11),1306-1325, https://doi.org/10.1002/ejhf.1594.
4. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị suy tim mạn tính. 2020. Quyết định 1762/QĐ-BYT ngày 17/04/2020.
5. Pardeep Jhund, Piotr Ponikowski, Kieran F. Docherty, Samvel B. Gasparyan, Michael Böhm et al. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021. 143(20), https://doi.org/10.1161/circulationaha.121.053659.
6. McMurray JJV, Solomon SD. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England J Med. 2019. 381(21),1995-2008, http://10.1056/NEJMoa1911303.
7. McDonagh TA, Metra M, Adamo M. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021. 42(36),3599-3726, https://doi.org/10.1093/eurheartj/ehab368.
8. AstraZeneca. Forxiga. 2023. Available from: https://www.mims.com/vietnam/drug/forxiga/local-product- insert/230717-proposed%20PIForxiga-CKD-vn.pdf.
9. Đoàn Chí Thắng, Lê Thị Thu Hường, Trần Tú Nguyên. Nghiên cứu hiệu quả điều trị thuốc dapagliflozin trên bệnh nhân suy tim phân suất tống máu thất trái giảm. Y học lâm sàng Bệnh viện Trung ương Huế. 2024. số 96/2024, 100-107, 10.38103/jcmhch.96.14.
10. Nguyễn Tá Đông, Trần Tú Nguyên, Phạm Quang Tuấn. Results of the Heart Failure Management Program at Hue Central Hospital after 1 year of implementation. Tạp chí Tim mạch học Việt Nam. 2023. Số 107E/2023, 18-24, https://doi.org/10.58354/jvc.107E.2023.711.
11. Docherty KF, Anand IS, Chiang CE, et al. Effects of dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia. 2022. 2(2),139-153, doi: 10.1016/j.jacasi.2022.02.004.